H.C. Wainwright has initiated coverage on Seaport Therapeutics with a buy rating, signalling confidence in the clinical-stage biopharmaceutical company’s pipeline of central nervous system (CNS) treatments. The analyst note, released earlier this week, underscores growing enthusiasm for CNS-focused biotechs among US-based investment houses.
Seaport Therapeutics, which is not listed on the London Stock Exchange, is developing novel therapies for neuropsychiatric conditions including depression and anxiety disorders. The buy rating from H.C. Wainwright comes as the broader biotech sector sees renewed interest from institutional investors, partly driven by advances in neuroscience and a wave of regulatory approvals for CNS drugs in the US and Europe.
For UK investors with exposure to international biotech through pension funds or diversified portfolios, the initiation of coverage is a positive signal for the subsector. However, Seaport remains a clinical-stage company with no approved products, meaning its share price could be volatile depending on trial results and regulatory milestones.
The FTSE 100 and FTSE 250 have seen mixed performance in the healthcare space this year, with UK-listed pharmaceutical giants such as AstraZeneca and GSK providing more stable returns. Smaller biotech names, by contrast, offer higher risk but potentially greater upside—a dynamic that H.C. Wainwright’s note highlights.
Analysts at H.C. Wainwright did not provide a specific price target in the available details, but the buy rating suggests the firm believes the current valuation does not fully reflect the potential of Seaport’s pipeline. The company is expected to release early-stage clinical data later this year, which could act as a major catalyst for the stock.